Cannabis stocks news - daily news on stocks on CSE, TSX, TSXV, OTC, NASDAQ and NYSE from InvestorIdeas.com
Thursday 31 October 2019
Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: (TSXV: $VGW.V) (NASDAQ: $SNDL) (TSXV: $GYSR.V) (NYSE: $ACB) (OTC: $OWPC)
Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: (TSXV:
$VGW.V) (NASDAQ: $SNDL) (TSXV: $GYSR.V)
(NYSE: $ACB)
(OTC: $OWPC)
Delta, Kelowna, BC –October 31, 2019 (Investorideas.com
Newswire) www.Investorideas.com, a global news source covering leading sectors
including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and
experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2019/cannabis-potcasts/10311VGW-SNDL-GYSR-ACB-OWPC.asp
Good afternoon and welcome to another episode of
Investorideas.com "Potcast" featuring cannabis news, stocks to watch
as well as insights from thought leaders and experts
In
today’s podcast we look at a few early announcements.
But
first, Kanvas™, creator of
innovative solutions designed to elevate the user experience for legal cannabis
and cannabidiol (CBD) consumers, announced its Child-Resistant Disposable Vaporizer is
the first all-in-one hardware solution to pass stringent child-resistant
testing, delivering the market’s first certified child-resistant complete vape
device.
Dedicated
to consumer vape safety, Kanvas engineered the first-of-its-kind
child-resistant vape pen utilizing an ingenious push-and-turn technology that
disengages the battery to prohibit device operation. This patent-pending
complete child-resistant solution was tested by an accredited laboratory to
meet the Consumer Product Safety Commission’s (CPSC) standards for
child-resistant packaging as stated in the Code of Federal Regulations Title
16, Section 1700.20. Additional benefits of Kanvas’ fail-safe design include
prolonged battery life, auto-firing restriction and protection from the very
first hit.
“We are
proud to be the first in our industry to introduce an end-to-end vape solution
with certified child-resistant functionality,” said Andy Fathollahi, Kanvas
CEO. “Unlike devices from other hardware manufacturers, the Kanvas
Child-Resistant Disposable Vaporizer is the first and only complete device that
offers peace of mind out of the box. We have a tremendous engineering
department that worked tirelessly to make our goal of child safety in the vape
category a reality.”
The Child-Resistant Disposable Vaporizer is
powered by Vapetelligence™, Kanvas’ exclusive temperature-controlled dosing
technology, and secured with a DualLock snap-on compression fit mouthpiece that
eliminates tampering and leaks. Composed of food-grade 18/10 stainless steel
and a ceramic core, its undetectable levels of heavy metals are 10 times lower
than the industry standard.
Valens GroWorks
Corp. (TSXV: VGW) (OTCQX: VGWCF), a vertically integrated provider of
industry leading extraction products and services; including a diverse suite of
extraction methodologies, next generation cannabinoid delivery formats and an
ISO 17025 accredited analytical lab announced a multi-year white label agreement with BRNT Ltd, a leading, premium, cannabis
ancillary company to launch a line of unique cannabis vape pens in Canada.
Under the terms of the Agreement, Valens will provide high-quality cannabis
extracts, filling services and national distribution of a line of
custom-formulated BRNT-branded vape pens.
The
initial term of the Agreement will be for two years, with two successive one
year renewal options, and relates to the production and sale of a guaranteed
minimum of 2.2 million BRNT-branded vape pens, with the gross revenue potential
to Valens under the Agreement of over $50 million in the first two years, all
subject to final acceptance from provincial distributors, including of the
proposed price per unit. Under the terms of the Agreement, the two parties will
split economics through a profit share structure reflective of the respective
efforts of each party. Valens expects
the first shipment under the Agreement to take place in the first fiscal
quarter of 2020. The Company currently holds all required licensing from Health
Canada to carry out its obligations under the Agreement.
BRNT
is known for its rapid national growth, brand quality, industry experience and
commitment to product excellence. BRNT currently participates in the ancillary
products sector providing premium, high-quality cannabis accessories that are
currently available in over 170 stores across Canada with international
expansion underway including its newest line, Made By: a line of single-source
cannabis extract vaporizers with uniquely designed hardware.
"As
Valens begins official production of next generation products for Cannabis 2.0,
we are excited to be collaborating with BRNT to bring to market a line of
differentiated, high quality, concentrate vape products for Canadian
consumers", said Tyler Robson, CEO of Valens GroWorks. "BRNT has
shown impressive sales growth and market understanding through its ancillary
offerings. In pairing their retail and product knowledge with Valens'
processing and product development capabilities we believe this provides a
solid foundation to provide a product with strong consumer appeal."
"Valens has demonstrated a commitment to
cannabis extraction on a global scale that is driven by passion and quality. It
was a natural fit for BRNT to collaborate with Valens to bring the Made By
vaporizers brand to life with a partner that can mirror our globally recognized
signature design aesthetic and brand development capabilities," said Simon
Grigenas, CEO of BRNT Group. "BRNT and Valens are setting a new industry
standard by creating meaningful brands and products through a focused,
profitable approach, as opposed to the traditional vertical integration seen
today."
Sundial Growers
Inc. (NASDAQ: SNDL) has successfully entered the Prince Edward Island market,
highlighting its intent to be in all Canadian provinces by the end of 2019.
Sundial's products are now available in seven provinces.
The company recently
announced that
it will release its third quarter financial results on November 13, 2019 after Nasdaq market closing.
"P.E.I.
has proven to have a keen cannabis culture, and we are looking forward to
meeting the province's strong consumer demand for high-quality cannabis
products," said Andrew Stordeur, President of Sundial's Canadian
operations. "Islanders are sophisticated consumers who want a wide range
of products to choose from. We are excited to add to P.E.I.'s product
offerings, so that consumers can have the cannabis premium experiences they
deserve," he added.
Sundial's
high-quality products will be available in all four P.E.I. Cannabis locations,
as well as on its e-commerce platform. Sundial's entrance into the P.E.I.
market will begin with its Sundial brand which will offer five product lines:
Calm, Ease, Flow, Lift and Spark. Each product is mindfully grown in small
batches and nurtured by master growers to cultivate consistent high-quality
cannabis that gives consumers a tailored experience.
The
first products available to P.E.I. consumers will be Lemon Riot and Citrus
Punch, two upbeat sativa-dominant hybrid strains under Sundial's Lift product
line. Products from the Lift series aim to improve mood and encourage social
interactions.
Sundial
is also the proud owner of the premium cannabis brand Top Leaf, which is
expected to be available in P.E.I. in the near future. Top Leaf is industry
recognized and supported by award-winning cultivars and loyal consumers.
Geyser Brands Inc.
(formerly Kanzen Capital Corp.) (TSX-V: GYSR) announced that it has signed a definitive joint
venture agreement with Factory Brewing Ltd. (DBA "Craft Collective")
to jointly develop, manufacture, market, and sell non-alcoholic
cannabis-infused beverage brands in Canadian markets in two phases.
Pursuant
to the terms of the JV Agreement, the Joint Venture will be structured as a new
company, with two standing committees for the purpose of collaboration and
cooperation on research, development and commercialization of its products. The
first committee will be dedicated to identifying, developing and testing
formulations for commercialization. The second committee will be dedicated to
identifying and evaluating brands, including those brands owned by the Company
and Craft Collective, for commercialization. Each committee will be comprised
of 3 members from each of Geyser Brands and Craft Collective with the necessary
expertise for each committee's mandate, with the Company appointing the Chair
of each committee. The resulting NewCo will combine the craft beverage
manufacturing, marketing and distribution expertise from Craft Collective with
Geyser Brands' cannabis expertise, including leveraging its licensed producer
facility, formulation expertise, and distribution channels.
Under
the terms of the JV Agreement, the NewCo will immediately commence developing
multiple product formulations and branding for both cannabis and non-cannabis
products for introduction into the Canadian market. Craft Collective and NewCo
will enter into a mutually agreeable non-cannabis product manufacturing and
sales agreement in which Newco will outsource to Craft Collective the
manufacturing and distribution of its non-cannabis products. Production of
non-cannabis products will take place at Craft Collectives' facility in
Vancouver, British Columbia. Upon receipt of regulatory approval for the production
of cannabis products, Craft Collective and NewCo will use commercially
reasonable efforts to enter into a definitive agreement in connection with the
day to day management of the NewCo by Craft Collective, on terms and conditions
mutually agreeable and customary in a transaction of this nature. Subject to
the terms of the JV Management Agreement, all cannabis products will be
manufactured at Geyser Brands' licensed facility in Port Coquitlam, British
Columbia.
Pursuant
to the terms of the JV Agreement, Geyser Brands will have a 75% interest in the
NewCo, with Craft Collective's 25% interest being reserved and issued upon
completion of certain conditions outlined in the JV Agreement, including
receipt of regulatory approval for the production of cannabis products, the
execution of the JV Management Agreement and the execution of a mutually
agreeable shareholder agreement . In the event the Issue Conditions are not
satisfied or waived by Geyser Brands on or before December 31, 2019, or such
other date as mutually agreed by the parties, there will be no obligation for
NewCo to issue any interest to Craft Collective.
Geyser
Brands CEO, Andreas Thatcher commented, "Geyser Brands continues to build
and lead the way in establishing its position as a health and wellness CPG
company that gives lift to products with the addition of cannabis. Partnering
with Craft Collective and jointly leveraging our unique areas of expertise will
allow both parties to enter this emerging market and develop high-quality non cannabis
and cannabis-infused beverages for the consumable cannabis market."
Craft
Collective CEO, Andrew Harris stated, "This joint venture between Craft
Collective and Geyser Brands marks an exciting milestone for our company as we
continue to release innovative beverage brands to market. We look forward to
launching impactful products through this combination of our expertise."
Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), the Canadian company defining the future
of cannabis worldwide, announced the launch of Ready for Edibles, a national bilingual campaign dedicated to
educating new and experienced cannabis consumers on responsible consumption and
safe storage of edibles products before
they become available for sale in December.
In the
visual style of Not Safe For Work (NSFW)¸the campaign creative will depict
blurred images of cookies, gummies and other edibles products stamped with the
wording: ADULTS ONLY, stating "Edibles are coming and they're not for
kids. Ask a budtender or learn more at www.readyforedibles.com"
The
campaign can be seen at cannabis retail outlets across Canada and will be
complemented online with digital assets as well as other out-of-home opportunities
to connect with consumers.
"The
roll-out of Aurora's next generation of high-quality cannabis products is very
exciting and we are proud to be able to offer new forms like vapes,
concentrates and edibles," said Terry Booth, CEO of Aurora. "We want
to make sure consumers have the information they need to understand the
differences in these products, how to consume them responsibly, and most
importantly, that they should be kept away from children and pets."
Educational
content will also focus on identifying signs of over-consumption, understanding
the differences in onset times and effects, cautions around mixing with alcohol
and driving while intoxicated. All of Aurora's NextGen cannabis products,
including cookies, gummies, chocolates and mints, will include the certified,
lab-tested concentration of THC and CBD.
One World Pharma
Inc. (OTC: OWPC),
a fully licensed pure-play cannabis and hemp ingredient producer in Colombia, announced the upcoming launch of the cannabis
industry’s first ‘Cannabis Futures’ program at their growing operations in
Colombia. OWP’s program is designed to support and fuel projected global
cannabis industry growth by allowing manufacturers to fix their price in
advance for cannabis and hemp derived ingredients produced by OWP at space
specifically allocated to each specific manufacturer at OWP’s cultivation
facilities in Colombia. The commoditized approach to sourcing hemp and cannabis
ingredients anticipates and recognizes the natural maturity of the legal
cannabis market and offers manufacturers of consumer-packaged goods (CPG) an
easy way to enter the cannabis products market with a consistent supply of
ingredients and predictable pricing.
With
the cannabis industry predicted to continue to rapidly expand, scalability is
an imperative in cannabis. One World Pharma believes that the future of
cannabis is as a commodity, similar to coffee beans or orange juice where ideal
ingredients are grown and sold to major consumer brands. While other cannabis
companies have focused on being vertical plays spanning from seed to
customer-facing dispensaries, One World Pharma is a pure-play cannabis business
focused on one thing- supplying high quality hemp and cannabis derived
ingredients to consumer brands. The upcoming launch of its Cannabis Futures
program will provide these brands with predictable pricing for consistent,
high-quality cannabis ingredients that allow them to keep their retail product
offering consistent both in the deliverable and pricing.
“At
its core, One World Pharma isn’t just a cannabis company, we’re an ingredients
company,” said Chief Executive Officer, Craig Ellins. “Cannabis is now a
commodity just like coffee or soybeans. We’re not interested in competing with
the big players getting into branded cannabis products. Instead, we want to
supply and enable them. Our Cannabis Futures program will provide major
beverage companies, foods companies, cosmetic companies and any other
enterprise looking to combine cannabis-based ingredients with their product
offering with a streamlined path to enter the cannabis market.”
The
Futures program will allow One World Pharma’s customers to commit to purchase a
fixed amount of hemp and cannabis derived ingredients that will be grown and
processed specifically to their unique requirements on land exclusively
dedicated to them. This will allow One World Pharma to offer these customers a
predetermined, consistent price for this future product. Customers will be able
to lock in stable pricing while One World Pharma will be able to more
accurately predict its own recurring revenue and optimize its growing
operations.
In
the future, One World Pharma believes that this model could lead to the
development of a global cannabis commodities exchange. “We want to be part of
creating the long-term global financial and supply chain structures for the
cannabis industry,” said Ellins. “Partnership is one of our core values and the
foundation of our socially responsible practices. We believe that strong
infrastructure and systems will benefit the entire industry.”
One
World Pharma’s socially responsible partnerships with indigenous communities
and local farmers in Colombia will offer scalability to support its Cannabis
Futures program and service the needs of large manufacturers, while blending
ancestral techniques with state-of-the-art technology in one of the most ideal
cannabis-growing locations in the world.
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement to
buy products or services or securities. Investors are reminded all investment
involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also
available on iTunes, Spotify, Google
Play Music, Stitcher, Spreaker, YouTube
via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
About Investorideas.com - News that Inspires Big
Investing Ideas Investorideas.com is a recognized news source
publishing third party news, research and original financial content. Learn
about investing in stocks and sector trends with our news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas Potcasts
Cannabis News and Stocks on the Move podcast and column, Cleantech and
Climate Change , Exploring Mining
the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info:
https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where
permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
SinglePoint (OTCQB: $SING) Launches Wholly Owned Brand 1606 Original Hemp
SinglePoint
(OTCQB: $SING) Launches Wholly Owned Brand 1606 Original Hemp
SinglePoint introduces -
1606 Original Hemp
PHOENIX - October 31, 2019 (Investorideas.com Newswire) SinglePoint,
Inc. (OTCQB:SING) has launched into the smokable hemp market, releasing its wholly owned
brand, 1606 Original Hemp. The brand will carry a variety of smokable hemp
products. Recently, the company presented at NACS 2019 and had a phenomenal
response driving the creation of 1606. To date, the company has shipped orders
to convenience store owners with a collective 250 doors and has interest from
over 100 parties that collectively have over 15,000 doors.
Read this in full at https://www.investorideas.com/CO/SING/news/2019/103111606OriginalHemp.asp
SinglePoint (SIGN): Original Hemp 1606 Cigarettes
The name derives from the first hemp crop planted in 1606 in North
America. SinglePoint has planned to expand the brand quickly through retail,
distribution, and a new ecommerce site currently in development.
In today's world, hemp is becoming very popular. The use of hemp has
evolved into diverse products such as lotions, oils, food, beverages, and
cigarettes. Smokable hemp is a developing trend, but is it a good way to
consume the cannabinoid? Here's what you need to know:
Hemp vs. Marijuana
Hemp and marijuana are both part of the cannabis family. However, hemp
will not get you high unlike marijuana, which is known for its psychoactive
effects. Marijuana has high levels of
THC, containing anywhere from 5%-35% whereas hemp has less than 0.3% THC. Hemp contains high cannabidiol (CBD) content which is not
psychoactive. Smoking hemp is a positive alternative to marijuana, "You get the same taste, the
same psychological feeling of smoking a joint, but without the high."
Replacing Tobacco
Pure American Hemp cigarettes (link) are nicotine and tobacco free. Some
research suggests that smoking hemp cigarettes could be a potential tool to
replace tobacco and nicotine addictions. According to a Brightfield Group
survey of more than 5,000 CBD users in the U.S.:
- 24% have used it to help quit smoking.
- Quitters are often replacing cigarettes
- with either smokable hemp or vaping.
- 41% of quitters have entirely replaced
- tobacco with hemp CBD.
Google trends reveals over the last year that hemp was researched more
often than tobacco and nicotine.
Initial Research
Initial research has shown CBDs ability to reduce cigarette consumption.
Researchers at University College London conducted a study of 24 smokers. Each were given an inhaler with
CBD or placebo. For one week they were to use the inhaler when they had the
urge to smoke. Those with placebo had no difference in cigarettes smoked, those
with the CBD inhaler significantly reduced the number of cigarettes smoked by
40%.
The Alternative Market
The Alternative Market has continued to grow drastically, 35%, from 2019
to 2018 while cigarettes stayed steady at 3.1%. With the addition of hemp
cigarettes and the recent vape scare, many assume the alternative market will
continue growing as people look for a "healthier for you" alternative
to cigarettes.
The Future
BDS Analytics and Arcview Market Research projects that the collective
market for CBD sales in the U.S. will surpass $20 billion by 2024 while New
York-based investment bank Cowen & Co, estimates that the market could pull
in $15 billion by 2025. The smokable hemp market currently represents
approximately 2% of the overall CBD market, but with a 250% growth from 2017 to
2018, Brightfield Group, a Chicago-based cannabis market research firm,
identifies dried and smokable hemp flowers as one of the fastest-growing
segments of the CBD market.
About SinglePoint, Inc.
SinglePoint, Inc (SING) is a technology and investment company with a
focus on acquiring companies that will benefit from the injection of growth
capital and technology integration. The company portfolio includes mobile payments,
ancillary cannabis services and blockchain solutions. Through acquisitions into
horizontal markets, SinglePoint is building its portfolio by acquiring an
interest in undervalued companies, thereby providing a rich, diversified
holding base. Through SingleSeed,
the company is providing products and services to the cannabis industry.
Connect on social media at:
Forward-Looking Statements
Certain statements in this news release may contain forward-looking
information within the meaning of Rule 175 under the Securities Act of 1933 and
Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the
safe harbor created by those rules. All statements, other than statements of
fact, included in this release, including, without limitation, statements
regarding potential future plans and objectives of the Company, are
forward-looking statements that involve risks and uncertainties. There can be
no assurance that such statements will prove to be accurate and actual results
and future events could differ materially from those anticipated in such
statements.
Technical complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined above. The
Company undertakes no duty to revise or update any forward-looking statements
to reflect events or circumstances after the date of this release.
Corporate Communication
SinglePoint Inc.
855-711-2009
investors@SinglePoint.com
SinglePoint.com
855-711-2009
investors@SinglePoint.com
SinglePoint.com
More info on SING at Investorideas.com Visit: https://www.investorideas.com/CO/SING/
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced
news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. For Disclosure purposes
SinglePoint Inc (OTCQB: SING) is a paid annual news and social media
company on Investorideas.com. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp and https://www.investorideas.com/About/News/Clientspecifics.asp . Learn more about our prices for publishing your
news release and our other news services on the Investorideas.com
newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to
regulations of each country. Please read Investorideas.com privacy
policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone
the use of cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Get more Cannabis Stock Investor Ideas - news,
articles, podcasts and stock
directories
Wednesday 30 October 2019
Investorideas.com - Drug Policy Alliance Statement on USDA Industrial Hemp Rules
Investorideas.com - Drug Policy Alliance Statement on USDA Industrial Hemp Rules
www.investorideas.com - news that inspires big ideas
www.investorideas.com - news that inspires big ideas
#Cannabis Industry Continues Global Expansion from #Israel to the EU; (CSE: $IPOT.C) (TSXV: $KHRN.V) (TSX: $AVCN.TO) (TSXV: $PCLO.V)
#Cannabis Industry Continues Global Expansion from #Israel to the EU;
(CSE: $IPOT.C) (TSXV: $KHRN.V) (TSX: $AVCN.TO) (TSXV: $PCLO.V)
Point
Roberts WA, Delta, BC – October 30, 2019 - Investorideas.com, a leading investor news resource
covering cannabis and hemp stocks releases a sector snapshot reporting on the
continued international expansion of the cannabis industry and how it’s leading
to a global cannabis infrastructure.
A
recent article reporting on the
growth of the global cannabis industry notes, “Fully 185 countries are
signatories to the United Nations’ Single Convention on Narcotic Drugs of 1961,
which prohibits cannabis as a drug that can be abused and cause ill effects,
without bringing a substantial therapeutic advantage. Each signatory’s laws
must reflect the Convention; that is the case for the US’ Controlled Substances
Act of 1971. Countries that have legalized cannabis are flouting the
convention, and some, such as Canada, admit that openly.”
“Thanks to changing public perceptions,
moves such as Canada’s, ongoing research on health benefits and risks, and the
urging of the World Health Organization—in 2019 it came out in favor of less
restrictive control of cannabis and of removing prohibitions for pure CBD and
CBD preparations containing no more than .2% THC—the United Nations has said it
will revisit cannabis under the Single Convention. It should be noted, however,
that amending the convention is difficult with so many members involved.”
“Medical
use of cannabis is and will be accepted around the world a lot more quickly
than recreational use,” says Mario
Torres
of Brazeau Seller Law (Ottawa, Ontario,
Canada). “People are not enthused about prohibiting medical care. They don’t
want to disallow access to the only thing that may stop epileptic seizures in
children or is part of a patient’s treatment plan.” Medical use is becoming
more acceptable even in very conservative countries like South Korea and
Thailand, which have legalized cannabis for medical purposes.
Recent
news headlines look to Israel
saying,” Israel is at the forefront of cannabis tech. The country, which
produces more pharmaceutical cannabis than just about anywhere else, is poised
to become a leading exporter.”
Recently
listed on the CSE, Isracann Biosciences Inc. (CSE:
IPOT)
is an Israeli-based cannabis company focused on becoming a premier cannabis
producer offering low-cost production targeting undersupplied, major European
marketplaces. The Company (formerly Atlas Blockchain Group Inc.), recently
provided an operative overview and update regarding facility development
activities in Israel.
Concurrent
to and as part of the Company’s recent listing on the Canadian Securities
Exchange it had satisfied the escrow release conditions for the net proceeds of
its highly successful CAD$10.1 million financing efforts which bolstered an
already healthy cash position.
This
positions the company to immediately accelerate its planned Phase One Facility
Design and Construction Services Program which consists of finalization of
greenhouse facility design for cannabis cultivation and production in
accordance with an existing technical specifications strategy; to rapidly
advance greenhouse and related facility construction per the design; ensure
adequate controls are in place against any diversion, theft and loss of
cannabis products per regulatory standards; and ensure compliance with other
protective security, health, and safety requirements in accordance with Israeli
regulations.
To
date, Isracann has entered into agreements for the development of medical
cannabis cultivation projects with regional stakeholders holding preliminary
breeding and cultivation licenses issued by the Israeli Ministry of Health. The
regional stakeholder is required to renew these licenses each year and further
bears the cost of electricity, property and related land taxes and are bound to
working with Isracann to obtain the required licenses and to participate in the
construction of the greenhouses.
Isracann
‘s CEO, Darryl Jones notes, “We are very pleased to have achieved our very
important initial milestone targets with the CSE listing of our ticker symbol
“IPOT” and to confirm our accelerated investment plans in Israel are fully
underway. We have lined up several key organizations and personnel and look
forward to announcing a number of these key commercial agreements in the days
and weeks ahead. We thank all our supporters for their belief in us, and in our
belief that the Israeli agricultural sector will provide a huge leading role in
positioning the Isracann brand as market leaders in the massive and underserved
European cannabis marketplace.”
In
related news, the Company welcomes the recent appointment of Irit Arbel, Ph.D.
to its Board of Directors. Dr. Arbel brings significant senior
multidisciplinary biopharma and governance experience to Isracann’s board. She
serves as CEO, Co-Founder and Director of Neurocords Ltd., a company focused on
developing new treatments for peripheral and spinal cord regeneration, and
previously served as Director and President of Brainstorm Cell Therapeutics,
and as Executive Vice President of Research and Development at Savicell Diagnostic,
a biotechnology company. Dr. Arbel previously served as Chairperson of Real
Aesthetics, a company specializing in cellulite ultrasound treatment, and BRH
Medical, a developer of medical devices for wound healing. She was also
Director of M&A at RFB Investment House, a private investment firm focusing
on early-stage technology-related companies. Previously, Dr. Arbel was
President and Chief Executive Officer of Pluristem Life Systems, a
biotechnology company, and prior to that as Israeli Sales Manager of Merck,
Sharp & Dohme, a pharmaceutical company. Dr. Arbel earned her Ph.D. in 1997
in Neurobiology, after performing research in the area of MS. Dr. Arbel also
holds a Chemical Engineering degree from the Technion, Israel’s Institute of
Technology.
Avicanna Inc.(TSX:
AVCN)
(OTCQX:
AVCNF),
a biopharmaceutical company focused on the development, manufacturing and
commercialization of cannabinoid-based products, recently
announced
that Santa Marta Golden Hemp S.A.S., its majority owned subsidiary, has completed
commercial exports of its Aureus™ brand of CBD-based products to South Africa
and the United Kingdom.
The
Aureus brand of products include an organic and sustainable line of
plant-derived active pharmaceutical ingredients ("APIs") and bulk CBD
formulations developed by Avicanna in collaboration with SMGH and Sativa Nativa
S.A.S. ("Sativa Nativa"), which is also a majority owned subsidiary
of Avicanna. These initial sales included the export of CBD isolate and 4% bulk
formulation for CBD oil sublingual sprays. Each of the above exports has been
completed in accordance with all applicable laws in the Jurisdictions.
Aras
Azadian, Avicanna's Chief Executive Officer, stated "We are excited to
bring the Aureus brand of cannabinoid APIs to our international customers. We
believe these initial sales further validate the brand's opportunities in these
two countries, as well as the potential for us to actively market our APIs
across the globe to manufacturers of CBD products. We believe the Aureus brand
of API products will become a leader in organic and sustainable cannabinoid raw
materials and the gold standard with respect to global quality controls, which
we believe are necessary for the evolution of a worldwide cannabinoid
industry.”
Avicanna
is also looking into the Latin American market having announced the retail launch
of its Pura Earth™ derma-cosmetics line of CBD products, which are now
available at approximately 59 high-end retail locations throughout Colombia,
including Blind Prestige beauty shops and Cromantic professional beauty
markets.
Khiron Life
Sciences Corp. (TSXV:
KHRN)
(OTC:
KHRNF),
a vertically integrated cannabis leader with core operations in Latin America, recently
announced
their entrance into the EU market having completed the EU cosmetic regulatory
process for seven Kuida products, and received a "no objection"
letter from TSXV with respect to distribution of these products in the UK.
Tejinder
Virk, President, Khiron Europe, commented, "The fulfillment of EU cosmetic
regulatory requirements allows the Company to bring our proven product line
into the sophisticated and growing European skincare market, where we expect to
rapidly build and grow Kuida's market share. We will initially focus on import
and marketing in UK, with our first sales expected in Q1 2020, before expanding
to Spain, Germany and the broader European market, subject to the specific
requirements of individual member states and TSXV approval."
Kuida®,
the first consumer brand of Khiron's wellness business unit, brings the
benefits of cannabidiol (CBD) to a comprehensive portfolio of skin and body
care products for women. Kuida was launched in Colombia in October 2018 through
retail, wholesale and online channels and is now available nationwide and
through e-commerce channels. As the Company expands Kuida® distribution in
Europe, the brand will be a featured exhibitor at Cosmoprof Worldwide Bologna
2020, which attracted over 265,000 visitors in 2019 and is the largest such
event to learn more about market leading products and to place orders.
The
company also participated
in
the Open Parliament held by Senate of Mexico on the theme of "Towards
Cannabis Regulation," which took place through August 2019 and September
2019. As a Latin American cannabis leader with a strong presence in Mexico,
Khiron joined both open forum sessions and a committee of experts to engage in
dialogue and provide input on the building blocks of the country's new
regulatory framework.
PharmaCielo Ltd. (TSXV:PCLO) (OTC:
PHCEF),
whose anticipated acquisition of Australian Securities Exchange
("ASX") listed Creso Pharma will establish a global medicinal
cannabis company positioned to rapidly develop new markets and grow sales in
the expanded footprint served by the combined company, recently announced key developments
in respect of its acquisition originally announced on June 6, 2019. Creso
Pharma has informed the Company that it has received approval from the Supreme
Court of Western Australia to convene meetings of its shareholders and listed
option holders, and if thought fit, to approve the Schemes of Arrangement
whereby PharmaCielo would acquire all of the issued and outstanding shares and
listed options of Creso Pharma. The Meetings will be held on November 11, 2019,
beginning at 10:00AM (Perth time).
The
Board of Directors of Creso Pharma continue to unanimously recommend that Creso
Pharma Shareholders and the Creso Pharma Optionholders vote in favour of the
proposed Schemes of Arrangement, in the absence of a superior proposal for
Creso Pharma.
David
Attard, CEO of PharmaCielo commented, "PharmaCielo's acquisition of Creso
Pharma, creates a combined company that has operational excellence across the
value chain. The quality and scale of PharmaCielo's cultivation and extraction
compliments Creso Pharma's product development and extensive developed global
sales channels. With the Creso Pharma acquisition and our recently announced agreement to export
CBD into the United States , 2020 is going to be an exciting year for
PharmaCielo shareholders."
PharmaCielo
expects that the combined company will be well-positioned to drive significant
value for both existing PharmaCielo and Creso Pharma shareholders.
PharmaCielo
has received conditional approval from the TSX Venture Exchange for the
issuance of common shares of PharmaCielo to Creso Pharma Shareholders and Creso
Pharma Optionholders in order to effect the Schemes of Arrangement. The
effective date of the Schemes of Arrangement is expected to be November 13,
2019; and the closing date of the acquisition is expected to be November 22,
2019.
With
the growing international acceptance of the cannabis industry, companies with
strongly established infrastructure in key global trade areas will become more
of an essential asset as the industry moves further towards global standards
and sales.
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third
party news, research and original financial content. Learn about investing in
stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining,
sports biotech, water, renewable energy and more. Investor Idea’s original
branded content includes the following podcasts and columns : Crypto
Corner , Play by Play sports and stock news
column, Investor
Ideas Potcasts Cannabis News and Stocks on
the Move podcast and column, Cleantech and Climate Change , Exploring Mining, the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital
publisher of third party sourced news, articles and equity research as well as
creates original content, including video, interviews and articles. Original
content created by investorideas is protected by copyright laws other than
syndication rights. Our site does not make recommendations for purchases or
sale of stocks, services or products. Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. All
investing involves risk and possible losses. This site is currently compensated
for news publication and distribution, social media and marketing, content
creation and more. Disclosure is posted for each compensated news release, content
published /created if required but otherwise the news was not compensated for
and was published for the sole interest of our readers and followers. Contact
management and IR of each company directly regarding specific questions.
Disclosure:
this news article featuring CSE: IPOT is
a paid for news release on Investorideas.com – third party (two thousand) More
disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about
publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global
investors must adhere to regulations of each country. Please read
Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Follow us on Social Media
Contact Investorideas.com
800-665-0411
Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock
directories
Subscribe to:
Posts (Atom)
What's up with Cannabis Stocks?
What's up with Cannabis Stocks? : What's up with Cannabis Stocks?
-
New #Cannabis Stocks Added to Investor Ideas; (TSX: $FAF.V) (CSE: $STIL.C) (CSE: $ORCD.C) (CSE: $VREO.C) (CSE: $PUMP.C) (OTC: $NUGL) ...
-
Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: Dixie Brands (CSE: $DIXI_U.C) (OTC: $DXBRF), Khiron Life Sciences (T...
-
Investorideas.com - CBD Stock News: InnoCan Pharma (CSE: INNO) Announces the Successful Completion of an Independent Clinical Study Demonstr...